Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 6

Results For "Granules"

90 News Found

Granules India chooses Veeam to protect digital business
Digitisation | May 30, 2022

Granules India chooses Veeam to protect digital business

Pharmaceutical manufacturer uses Veeam solutions to accelerate mission-critical backups by 95% and restore data in minutes, not hours


Granules Pharmaceuticals clears USFDA audit
News | March 15, 2022

Granules Pharmaceuticals clears USFDA audit

This is the sixth successful USFDA audit for this facility


Granules India Q3FY22 PAT at Rs 100.88 cr.
News | February 08, 2022

Granules India Q3FY22 PAT at Rs 100.88 cr.

Granules India has reported consolidated financial results for the period ended December 31, 2021


Granules receives ANDA approval for anti-depressant medication
Drug Approval | February 03, 2022

Granules receives ANDA approval for anti-depressant medication

It has a total of 50 ANDA approvals from USFDA


Granules Pharmaceuticals concludes USFDA audit with three minor observations
News | January 31, 2022

Granules Pharmaceuticals concludes USFDA audit with three minor observations

The audit is a PAI for two of its product applications filed from this facility


Granules receives ANDA approval for potassium chloride for oral solution USP, 20 mEq
Drug Approval | January 28, 2022

Granules receives ANDA approval for potassium chloride for oral solution USP, 20 mEq

Potassium chloride is used to prevent or to treat low blood levels of potassium


Dr. K.V.S Ram Rao is the new JMD & CEO of Granules India
People | January 05, 2022

Dr. K.V.S Ram Rao is the new JMD & CEO of Granules India

He has over 29 years of experience in the field of manufacturing, R&D, business and customer service management


Granules receives ANDA approval for amphetamine mixed salts
Drug Approval | December 30, 2021

Granules receives ANDA approval for amphetamine mixed salts

The current annual U.S. market for amphetamine mixed salts, USP 1.25mg, 1.875mg, 2.5mg, 3.125mg, 3.75mg, 5mg, 7.5mg immediate release tablets strengths is approximately US $ 335 million, according to MAT, Oct 2021 IQVIA/IMS Health


Granules Inc., receives ANDA approval for prazosin hydrochloride
Drug Approval | December 28, 2021

Granules Inc., receives ANDA approval for prazosin hydrochloride

The current annual U.S. market for prazosin hydrochloride 1mg, 2mg, 5mg strengths is approximately US $ 54 million, according to IQVIA/IMS Health


Granules India appoints Sucharita Rao Palepu as Non-executive Independent Director
People | December 24, 2021

Granules India appoints Sucharita Rao Palepu as Non-executive Independent Director

Sucharita brings with her a rich and varied experience of two decades in Information Technology and Financial Services